SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-010064
Filing Date
2022-05-16
Accepted
2022-05-16 16:03:07
Documents
68
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q spro-20220331.htm   iXBRL 10-Q 2857530
2 EX-31.1 spro-ex31_1.htm EX-31.1 12593
3 EX-31.2 spro-ex31_2.htm EX-31.2 12622
4 EX-32 spro-ex32.htm EX-32 11154
  Complete submission text file 0000950170-22-010064.txt   10248090

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT spro-20220331_def.xml EX-101.DEF 303188
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT spro-20220331.xsd EX-101.SCH 81382
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT spro-20220331_lab.xml EX-101.LAB 574125
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT spro-20220331_cal.xml EX-101.CAL 43292
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT spro-20220331_pre.xml EX-101.PRE 454188
62 EXTRACTED XBRL INSTANCE DOCUMENT spro-20220331_htm.xml XML 1819450
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38266 | Film No.: 22928628
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences